Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Hypothetical WD-repeat protein F21H12.1 in chromosome II | 0.0158 | 0.0683 | 0.0683 |
Trichomonas vaginalis | retinoblastoma binding protein, putative | 0.0158 | 0.0683 | 0.0683 |
Onchocerca volvulus | 0.1064 | 1 | 0.5 | |
Plasmodium falciparum | SPRY domain, putative | 0.0091 | 0 | 0.5 |
Echinococcus granulosus | wd40 repeat | 0.0158 | 0.0683 | 0.0683 |
Loa Loa (eye worm) | hypothetical protein | 0.0158 | 0.0683 | 0.0683 |
Loa Loa (eye worm) | WD40 repeat protein | 0.1064 | 1 | 1 |
Echinococcus multilocularis | protein will die slowly | 0.1064 | 1 | 1 |
Echinococcus granulosus | protein will die slowly | 0.1064 | 1 | 1 |
Echinococcus multilocularis | wd40 repeat | 0.0158 | 0.0683 | 0.0683 |
Schistosoma mansoni | retinoblastoma binding protein | 0.0158 | 0.0683 | 0.0683 |
Schistosoma mansoni | hypothetical protein | 0.1064 | 1 | 1 |
Trichomonas vaginalis | WD repeat domain, putative | 0.1064 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0158 | 0.0683 | 0.0683 |
Plasmodium vivax | hypothetical protein, conserved | 0.0091 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | Antifungal activity against Candida albicans ATCC 44859 assessed as growth inhibition after 24 to 48 hrs by microbroth dilution method | ChEMBL. | 23659859 | |
GI (functional) | Antibacterial activity against Escherichia coli CCM 4517 assessed as growth inhibition after 24 to 48 hrs by microbroth dilution method | ChEMBL. | 23659859 | |
MIC (functional) | = 25 ug ml-1 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition after 14 days by microdilution method | ChEMBL. | 23659859 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.